Cargando…
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
BACKGROUND: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolescents, demonstrating improvements in health-related Q...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240555/ https://www.ncbi.nlm.nih.gov/pubmed/37283819 http://dx.doi.org/10.1177/20406207231170701 |
_version_ | 1785053788522938368 |
---|---|
author | Astermark, Jan Hermans, Cédric Ezzalfani, Monia Sidhom, Alaeddine Barbier, Sylvaine Kragh, Nana Falk, Aletta Eriksson, Daniel |
author_facet | Astermark, Jan Hermans, Cédric Ezzalfani, Monia Sidhom, Alaeddine Barbier, Sylvaine Kragh, Nana Falk, Aletta Eriksson, Daniel |
author_sort | Astermark, Jan |
collection | PubMed |
description | BACKGROUND: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolescents, demonstrating improvements in health-related QoL (HRQoL) when assessed by the haemophilia-specific QoL (HaemAQoL) questionnaire. OBJECTIVE: To describe in depth the evolution of QoL, pain- and activity-related domains and questions for pediatric, adolescent, and adult patients with hemophilia B treated with rFIXFc prophylaxis. DESIGN: A post hoc analysis of data from a series of clinical trials. METHODS: This post hoc, long-term analysis assessed patient-reported outcomes (PROs) from the Kids B-LONG (NCT01440946: pediatric) and B-LONG (NCT01027364: adults and adolescents) parent studies and the B-YOND (NCT01425723: all age groups) extension study. RESULTS: Ninety-two adult and adolescent patients that started in the B-LONG study were assessed, with a median (range) duration of follow-up of 58.9 (0.0–78.4) months. The Haem-A-QoL total score was significantly reduced from baseline by 4.45 (p ⩽ 0.01), as were the subdomains ‘physical health’ (9.10; p = 0.001), ‘sports and leisure’ (11.25; p ⩽ 0.01), ‘treatment’ (2.69; p = 0.05), and ‘view of self’ (5.81; p = 0.002). Thirty pediatric patients that started in the Kids B-LONG study were assessed, with a median (min–max) duration of follow-up of 36.7 (9.0–59.9) months. The high level of satisfaction demonstrated by the PROs at baseline was maintained. CONCLUSION: rFIXFc prophylaxis reduced perceived pain and increased levels of physical activity with sustained, long-term improvements in QoL in adult and adolescent patients with hemophilia B and maintained high QoL scores in pediatric patients. |
format | Online Article Text |
id | pubmed-10240555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-102405552023-06-06 Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes Astermark, Jan Hermans, Cédric Ezzalfani, Monia Sidhom, Alaeddine Barbier, Sylvaine Kragh, Nana Falk, Aletta Eriksson, Daniel Ther Adv Hematol Original Research BACKGROUND: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolescents, demonstrating improvements in health-related QoL (HRQoL) when assessed by the haemophilia-specific QoL (HaemAQoL) questionnaire. OBJECTIVE: To describe in depth the evolution of QoL, pain- and activity-related domains and questions for pediatric, adolescent, and adult patients with hemophilia B treated with rFIXFc prophylaxis. DESIGN: A post hoc analysis of data from a series of clinical trials. METHODS: This post hoc, long-term analysis assessed patient-reported outcomes (PROs) from the Kids B-LONG (NCT01440946: pediatric) and B-LONG (NCT01027364: adults and adolescents) parent studies and the B-YOND (NCT01425723: all age groups) extension study. RESULTS: Ninety-two adult and adolescent patients that started in the B-LONG study were assessed, with a median (range) duration of follow-up of 58.9 (0.0–78.4) months. The Haem-A-QoL total score was significantly reduced from baseline by 4.45 (p ⩽ 0.01), as were the subdomains ‘physical health’ (9.10; p = 0.001), ‘sports and leisure’ (11.25; p ⩽ 0.01), ‘treatment’ (2.69; p = 0.05), and ‘view of self’ (5.81; p = 0.002). Thirty pediatric patients that started in the Kids B-LONG study were assessed, with a median (min–max) duration of follow-up of 36.7 (9.0–59.9) months. The high level of satisfaction demonstrated by the PROs at baseline was maintained. CONCLUSION: rFIXFc prophylaxis reduced perceived pain and increased levels of physical activity with sustained, long-term improvements in QoL in adult and adolescent patients with hemophilia B and maintained high QoL scores in pediatric patients. SAGE Publications 2023-05-29 /pmc/articles/PMC10240555/ /pubmed/37283819 http://dx.doi.org/10.1177/20406207231170701 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Astermark, Jan Hermans, Cédric Ezzalfani, Monia Sidhom, Alaeddine Barbier, Sylvaine Kragh, Nana Falk, Aletta Eriksson, Daniel Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes |
title | Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes |
title_full | Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes |
title_fullStr | Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes |
title_full_unstemmed | Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes |
title_short | Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes |
title_sort | recombinant factor ix fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia b: post hoc analysis of phase iii trials using patient-reported outcomes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240555/ https://www.ncbi.nlm.nih.gov/pubmed/37283819 http://dx.doi.org/10.1177/20406207231170701 |
work_keys_str_mv | AT astermarkjan recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT hermanscedric recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT ezzalfanimonia recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT sidhomalaeddine recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT barbiersylvaine recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT kraghnana recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT falkaletta recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes AT erikssondaniel recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes |